tofacitinab

Targeted treatments for atopic dermatitisEmerging treatments are expected to help fill the need for safer and more effective therapies for atopic dermatitis (AD). Both systemic and topical treatments are needed to provide full and complete treatment for patients with AD. Targeting the specific axis or axes that control AD may contribute to developing personalized approaches to treatment
New rheumatoid arthritis therapies are comingFour new drugs and a biosimilar should be on your radar.
New outcomes data to be included on Xeljanz labelsFDA has approved the supplemental New Drug Application for tofacitinib citrate (Xeljanz, Pfizer) to include additional patient-reported outcomes data on the label.
First JAK inhibitor approved as second-line RA treatmentTofacitinab approved for 5-mg tablets for the treatment of adult patients with moderately to severely active rheumatoid arthritis unhealed by methotrexate